Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMcbride Regulatory News (MCB)

Share Price Information for Mcbride (MCB)

Share Price is delayed by 15 minutes
Get Live Data
146.20    4.60 (3.25%)
Bid:
145.00
Ask:
146.60
Spread: 1.60 (1.103%)
Market Cap: £249.80m
MCB Live PriceLast checked at - London Stock Exchange

Intraday Mcbride Share Chart

Refinancing on improved terms

27 Jun 2017 07:00

RNS Number : 2177J
McBride PLC
27 June 2017
 

27 June 2017

 

McBride plc

 

Refinancing on improved terms

 

McBride plc ("the Group"), the leading European manufacturer and supplier of Co-manufactured and Private Label products for the Household and Personal Care market, today announces the refinancing of the Group in further support of the Group's Repair, Prepare, Grow strategy.

 

The Group has secured replacement banking facilities from a panel of international banks and using these increased facilities will repay its US Private Placement Notes ("USPP"). These actions will lower the cost of the Group's debt financing from the financial year starting on 1 July 2017 by approximately £2.0m per year.

 

 

Replacement Bank Facilities

 

The existing EUR 140m multi-currency revolving credit facility ("RCF") has been increased to a five year EUR 175m facility with a maturity of June 2022.

 

Features of the replacement facilities include:

 

- a EUR 175m RCF of which approximately EUR 70m will be drawn, providing the Group with significant committed funding headroom

- a 5 bps reduction in both margin and non-utilisation fees

- the addition of further borrowing entities and currencies, increasing flexibility going forward

- a EUR 75m uncommitted accordion feature will provide additional facilities for potential future acquisitions in support of the Grow phase of our strategy

 

The bank facilities are provided by a syndicate of HSBC, KBC, Bayern LB, BNP Paribas and Barclays.

 

US Private Placement Notes

 

The existing $50m 5.51%1 2020 USPP and $40m 5.38%1 2022 USPP will be repaid in full by drawing on the increased RCF.

 

Under the terms of the USPP arrangements, the Group will pay a 'make-whole' payment to existing USPP note-holders of approximately £11m2. At the same time the Group will close out the Euro/Dollar cross-currency interest rate swaps relating to the existing USPP notes which have a current mark-to-market net value of approximately £11m3 in favour of the Group.

 

Financing charges

 

Based on the current level of borrowings and interest swap rates, and taking into consideration the amortisation of initial fees, the Group's pro forma annual underlying finance charge will, over a full year, reduce by approximately £2m4 per annum. The Group's overall ongoing average cost of debt, after the repayment of the USPP, will reduce by approximately 310bps 4 to 150bps.

 

The 'make whole' payment to USPP note-holders will be treated for the Group's financial statements for the 12 months to 30 June 2017 as an exceptional finance charge. The total exceptional finance charge associated with this transaction will be approximately £13m comprising the make whole payment and additional USPP closure costs.

 

Net Debt

 

Following completion of all the transactions surrounding this change, which are expected by 30 June 2017, the impact on the Group's current net debt level will remain broadly unaffected.

 

 

Chris Smith, Chief Financial Officer of McBride, commented:

 

"As we prepare for the Grow phase of our strategy, we have secured an improvement in the cost, flexibility and duration of our banking facilities. The completion of this exercise represents another important milestone in the delivery of Repair, Prepare and Grow and reflects the strong ongoing support from our chosen banks."

 

 

Notes

1 - Adjusted for the impact of cross currency swap agreements.

2 - Will be treated as exceptional finance costs. Value estimated as at 23 June 2017.

3 - Will be treated as a movement on the derivative already reported in our income statement. Value estimated as at 23 June 2017.

4 - As compared to the position at 30 June 2016

 

 

For further information please contact:

 

McBride plc

Chris Smith, Chief Financial Officer

0161 203 7570

FTI Consulting

Ed Bridges, Nick Hasell

020 3727 1017

 

Note: This announcement contains inside information which is disclosed in accordance with the Market Abuse Regulation which came into effect on 3 July 2016.

 

-Ends-

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCFFMPTMBITBIR
Date   Source Headline
23rd Jun 20094:14 pmRNSHolding(s) in Company
22nd Jun 200910:18 amRNSHolding(s) in Company
15th May 20094:18 pmRNSDirector/PDMR Shareholding
13th May 200912:00 pmRNSHolding(s) in Company
30th Apr 20093:17 pmRNSBlocklisting Six Monthly Return
30th Apr 20097:00 amRNSInterim Management Statement
28th Apr 200911:27 amRNSHolding(s) in Company
6th Apr 200912:05 pmRNSDirectorate Change
26th Mar 20092:03 pmRNSAppointment of Broker
10th Mar 20093:39 pmRNSDirector/PDMR Shareholding
5th Feb 20097:00 amRNSInterim Results
22nd Jan 200910:50 amRNSHolding(s) in Company
16th Jan 20093:16 pmRNSHolding(s) in Company
15th Jan 20094:51 pmRNSHolding(s) in Company
29th Dec 20084:41 pmRNSSecond Price Monitoring Extn
29th Dec 20084:36 pmRNSPrice Monitoring Extension
18th Dec 200810:30 amRNSHolding(s) in Company
18th Dec 20087:00 amRNSTrading Statement
3rd Dec 20084:35 pmRNSPrice Monitoring Extension
27th Nov 20084:37 pmRNSPrice Monitoring Extension
11th Nov 20082:47 pmRNSHolding(s) in Company
3rd Nov 200811:44 amRNSHolding(s) in Company
29th Oct 200810:59 amRNSBlocklisting Interim Review
27th Oct 20087:00 amRNSInterim Management Statement
16th Oct 20082:29 pmRNSDirector/PDMR Shareholding
14th Oct 20087:00 amRNSAnnual Information Update
24th Sep 200810:42 amRNSAnnual Report and Accounts
16th Sep 200811:06 amRNSDirector Declaration
5th Sep 20085:43 pmRNSHolding(s) in Company
5th Sep 200812:12 pmRNSDirector/PDMR Shareholding
4th Sep 20087:00 amRNSPreliminary Results
18th Jul 20082:56 pmRNSDirector Declaration
4th Jul 20084:34 pmRNSDirector/PDMR Shareholding
1st Jul 20087:00 amRNSTrading Statement
19th Jun 200812:20 pmRNSNotice of Trading Statement
11th Jun 20082:30 pmRNSDirector/PDMR Shareholding
29th May 20083:27 pmRNSDirectorate Change
9th May 200811:26 amRNSHolding(s) in Company
1st May 20083:49 pmRNSBlock Listing Cancellation
29th Apr 200810:41 amRNSBlocklisting Interim Review
29th Apr 200810:34 amRNSBlocklisting Interim Review
29th Apr 20087:01 amRNSDirectorate Change
29th Apr 20087:01 amRNSInterim Management Statement
28th Apr 200810:49 amRNSNotice of IMS
11th Apr 200810:48 amRNSHolding(s) in Company
2nd Apr 20082:18 pmRNSDirector/PDMR Shareholding
17th Mar 200810:59 amRNSDirector/PDMR Shareholding
10th Mar 20089:41 amRNSChange of Address
7th Mar 20084:34 pmRNSDirector/PDMR Shareholding
4th Mar 200812:58 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.